Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Level 5 - mechanism / opinion, no new human data
Preclinical animal (nonhuman primate) study without human data.
PubMed 16437566 · doi:10.1002/ana.20738
What was done
Researchers evaluated the effect of docosahexaenoic acid (DHA) on levodopa-induced dyskinesias (LIDs) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated parkinsonian monkeys across two experimental setups: one group primed with levodopa for several months before DHA administration, and another de novo group treated with DHA prior to initiating levodopa therapy.
What was found
The abstract reports no numerical data or statistical measures. It states that DHA reduced LIDs in both paradigms without altering the antiparkinsonian efficacy of levodopa, suggesting it can lessen severity and delay LID development.
Why it matters
If translatable to humans, dietary or therapeutic supplementation with DHA could help mitigate a major dose-limiting complication of long-term levodopa therapy in Parkinson's disease.
Limits
The study was conducted entirely in an MPTP nonhuman primate model rather than humans. The abstract does not disclose the sample size, specific DHA dosages, duration of treatment, or quantitative effect sizes and variance measures.
Cited by
- supports DHA omega-3 fatty acids may protect against dopamine-producing neuron loss and prevent levodopa-induced dyskinesias in Parkinson's disease.
- supports High doses of DHA reduce L-dopa-induced dyskinesias in both rodent and non-human primate MPTP models of Parkinson's disease.